Kelyrab-DSR Capsule is a combination pharmaceutical formulation containing Domperidone 30 mg and Rabeprazole 20 mg, designed for the management of gastrointestinal disorders characterized by acid reflux and delayed gastric emptying. Domperidone, a peripheral dopamine D2 receptor antagonist, enhances gastrointestinal motility by increasing the tone of the lower esophageal sphincter and accelerating gastric emptying, thereby alleviating symptoms such as nausea, vomiting, and bloating. Rabeprazole, a proton pump inhibitor (PPI), suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system in the gastric parietal cells, providing effective relief from acid-related conditions including gastroesophageal reflux disease (GERD), erosive esophagitis, and peptic ulcers. The synergistic action of these two agents in Kelyrab-DSR Capsule offers both symptomatic relief and mucosal healing by addressing both motility and acid secretion abnormalities. This combination is typically prescribed for patients with GERD accompanied by delayed gastric emptying or dyspepsia unresponsive to monotherapy. Kelyrab-DSR should be used under medical supervision, with caution in patients with cardiac arrhythmias, hepatic impairment, or known hypersensitivity to either component. Adherence to prescribed dosage and duration is essential to optimize therapeutic outcomes and minimize potential adverse effects.